Revvity is like Thermo Fisher Scientific for specialized life science and diagnostic solutions.

Revvity is similar to Agilent Technologies for advanced scientific instruments and diagnostic tools.

• Life Sciences Research Instruments & Reagents: Provides specialized laboratory instruments, reagents, and consumables used in drug discovery, genomics, cell biology, and other advanced research applications.
• Diagnostic Solutions: Offers a range of products and services for disease detection, including newborn screening, prenatal testing, and infectious disease diagnostics.
• Informatics Software & Services: Delivers software platforms and data analytics solutions to manage, analyze, and interpret complex biological and clinical data.

Revvity (symbol: RVTY) primarily sells its products and services to other companies and institutions, making it a business-to-business (B2B) company.

Revvity does not publicly disclose the names of specific major customers in its financial reports or other public statements. This is common for companies like Revvity, which serve a broad and diverse customer base across multiple segments globally. Instead of individual company names, their customer base can be described by the following major categories of organizations they serve:

• Pharmaceutical and Biotechnology Companies: These companies are major customers, utilizing Revvity's life science research tools, reagents, software, and services for drug discovery, development, and manufacturing processes. This category includes a vast number of public and private companies globally.
• Academic and Government Research Institutions: Universities, research hospitals, and government laboratories (such as those funded by organizations like the National Institutes of Health (NIH)) are significant customers, relying on Revvity's solutions for fundamental and applied scientific research. These are typically not public companies.
• Clinical Diagnostic Laboratories and Healthcare Providers: Revvity's diagnostic products, used for areas like reproductive health, infectious disease testing, and applied genomics, are sold to clinical laboratories, hospitals, and other healthcare providers. This category includes both large public laboratory networks and smaller private entities.
• Food, Environmental, and Industrial Markets: This segment encompasses companies and laboratories in various industries that require analytical solutions for quality control, safety testing, and compliance. Examples include food and beverage manufacturers, environmental testing firms, and industrial research and quality control labs. This category includes a mix of public and private companies.

Prahlad Singh President and Chief Executive Officer

Prahlad Singh was appointed President and Chief Executive Officer of Revvity (formerly PerkinElmer) in December 2019, having joined the company in May 2014 as President of the Diagnostics business. He led the company through a significant transformation, including navigating the COVID-19 pandemic and overseeing its portfolio evolution. Notably, he was at the helm when the company completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a transaction that resulted in the creation of Revvity. Prior to Revvity, he served as General Manager of GE Healthcare's Women's Health business from 2012 to 2014. His career also includes senior executive roles in strategy, business development, and mergers and acquisitions at both GE Healthcare and Philips Healthcare. Earlier, from 1995 to 2007, he held leadership positions at DuPont Pharmaceuticals and Bristol-Myers Squibb Medical Imaging. Dr. Singh holds a PhD in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University.

Max Krakowiak Senior Vice President and Chief Financial Officer

Max Krakowiak serves as the Senior Vice President and Chief Financial Officer at Revvity, a role he assumed in 2023, following his appointment as CFO of PerkinElmer in August 2022. He has been a key member of Revvity's finance leadership team since 2018. Before his current position, he was the Vice President of Corporate Finance, overseeing financial planning and analysis, as well as commercial and business development finance. Krakowiak spent seven years at GE, most recently as a member of the executive leadership team in the company's corporate audit staff, where he oversaw teams responsible for corporate strategy, external investigations, and investor relations across global operating segments. He is also an alumnus of the GE Financial Management leadership program. Additionally, he had a brief career as a minor league baseball player for the Seattle Mariners organization. Krakowiak earned a bachelor's degree in finance from Fordham University.

Joel Goldberg Senior Vice President, Administration, General Counsel and Secretary

Joel Goldberg holds the position of Senior Vice President, Administration, General Counsel and Secretary at Revvity. In this role, he provides expert insights and strategic guidance on a range of legal, regulatory, and policy matters affecting the company. He leads dedicated teams focused on providing collaborative support and guidance across various corporate issues and business functions.

Magali Four Senior Vice President, Chief People and Culture Officer

Magali Four is the Senior Vice President, Chief People and Culture Officer at Revvity. (Detailed background information was not available in the provided search results.)

Tajinder Vohra Senior Vice President of Global Operations

Tajinder Vohra serves as the Senior Vice President of Global Operations at Revvity, a role he has held since 2015. He is responsible for overseeing the company's manufacturing, supply chain, customer care, and distribution functions. With nearly 30 years of experience in operations management, he leads a global team that collaborates closely with R&D and Product Management to facilitate the launch and manufacturing of products across Revvity's Life Sciences and Diagnostics businesses.

The rapid acceleration and adoption of artificial intelligence (AI), machine learning (ML), and advanced computational biology platforms represent an emerging threat. These technologies are increasingly capable of dramatically accelerating drug discovery, target identification, and diagnostic insights with potentially reduced reliance on traditional, iterative wet lab experimentation that underpins demand for Revvity's specialized laboratory instruments and reagents. As AI-driven solutions become more predictive and efficient, they could lead to a fundamental shift in research and diagnostic paradigms, potentially commoditizing certain physical lab tools or reducing the overall volume of specialized reagent consumption by making discovery more computationally intensive. Additionally, the rise of cloud-native, integrated data platforms and open-source lab automation solutions offers alternatives to Revvity's proprietary ecosystems, enabling labs to build more flexible, vendor-agnostic infrastructures that could diminish the value proposition of tightly bundled, proprietary offerings.

Revvity (symbol: RVTY) operates in significant global markets for its life sciences and diagnostics products and services. The company's estimated total addressable market (TAM) globally exceeds $60 billion.

More specifically, Revvity is a key player in several large and growing segments:

• Genomics Market: The global genomics market was valued at approximately US$42.6 billion in 2024 and is projected to reach US$66.8 billion by 2029.
• Proteomics Market: The global proteomics market was valued at approximately US$33.64 billion in 2024 and is projected to reach US$60.36 billion by 2029. Other estimates place the global proteomics market size at $32.8 billion in 2023, with a projection to reach $161.9 billion by 2035, or $24.2 billion in 2023, projected to reach $73.9 billion by 2032.
• Molecular Cytogenetics Market: The global molecular cytogenetics market size is estimated at USD 2.86 billion in 2025 and is projected to grow to approximately USD 7.82 billion by 2034. For the U.S. specifically, this market is valued at USD 962.90 million in 2025 and is projected to reach around USD 2,650.16 million by 2034.

Expected Drivers of Future Revenue Growth for Revvity (RVTY)

Revvity (NYSE: RVTY) is anticipated to drive future revenue growth over the next 2-3 years through several key areas, as indicated by recent earnings calls and analyst commentary:

1. Continued Strength in the Diagnostics Segment: The Diagnostics business is consistently highlighted as a strong performer, with specific mentions of robust growth in reproductive health and immunodiagnostics. This segment "continues to do very well" and led growth with a 3% revenue increase in Q3 2025. The specialty diagnostic businesses have "strong and durable underlying market growth drivers that are more immune to changes in the macroeconomic environment".
2. Expansion of the Software Business, particularly the Signals Software Franchise: Revvity's software business has demonstrated strong performance. The "Signals software franchise" exhibited approximately 30% organic growth in Q2 2025, contributing significantly to the Life Sciences segment's organic growth.
3. Launch of New Products, including AI-driven Solutions, and Strategic Partnerships: The company's President and CEO, Prahlad Singh, emphasized that "key new product launches and strategic partnership initiatives" are coming to fruition and positioning the company for greater success in 2026 and beyond. AI-driven product launches have also been specifically highlighted as growth drivers.
4. Recovery in Broader Industry Demand and Customer Activity: While the instrumentation business has faced challenges, management has noted a "path to recovery" and "improving signs of customer activity". The company is "positioned well to have a strong finish to the year with positive momentum as we head into 2026," contingent on sustained improvements in broader industry demand trends.
5. Growth in the Reagents Business within Life Sciences: Despite declines in the instrumentation aspect of the Life Sciences segment, the reagents business has shown "solid growth". This indicates a resilient component within the Life Sciences portfolio that is expected to contribute to overall revenue.

Share Repurchases

• In October 2024, Revvity's Board of Directors authorized a new two-year $1 billion share repurchase program, which superseded a prior program announced in May 2023.
• Under the buyback program announced in November 2024, Revvity had repurchased shares totaling $627.06 million as of August 5, 2025.
• During the three months ended September 29, 2024, the company repurchased $153.4 million in common stock.

Share Issuance

• Revvity issued 14,339 shares of common stock in fiscal year 2024 under its Employee Stock Purchase Plan at a weighted-average price of $99.62 per share.
• In fiscal year 2023, 28,899 shares were issued at a weighted-average price of $108.37 per share through the Employee Stock Purchase Plan.
• For fiscal year 2022, 30,818 shares were issued under the Employee Stock Purchase Plan at a weighted-average price of $134.05 per share.

Outbound Investments

• In 2021, Revvity (operating as PerkinElmer at the time) acquired BioLegend, a global provider of life science antibodies and reagents, for $5.7 billion (net of cash acquired).
• Also in 2021, the company acquired Nexcelom and Oxford Immunotec for an aggregate of $1.2 billion, aiming to enhance its Life Sciences and Diagnostics segments.

Capital Expenditures

• Revvity reported capital expenditures of $86.6 million for fiscal year 2024, an increase from $81.4 million in fiscal year 2023.
• The company anticipates an increase in capital expenditures for fiscal year 2025, driven by a strategic focus on enhancing digital capabilities, product innovations, and realigning production infrastructure.
• Capital expenditure remains a pressured area, with a focus on regional manufacturing and investments in differentiated specialty diagnostics.